Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Microcide, Naeja develop antifungals

Executive Summary

Microcide Pharmaceuticals (antimicrobials) will team up with Naeja Pharmaceutical (infectious diseases and cancer) to discover, develop, and market drugs. Naeja will contribute its azole antifungals, which reduce resistance mechanisms of fungal pathogens, to be used with Microcide's fungal efflux pump inhibitor leads.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies